Epilepsy is a neurological disorder characterized by recurring and unpredictable seizures. It is caused by abnormal electrical activity in the brain, which may be the result of genetic, metabolic, or other neurological factors. Seizures can affect motor control, mental state, sensory perception, mood, and even cause loss of consciousness. Epilepsy can be triggered by a variety of possible causes, including head trauma, stroke, brain tumour, infection, certain medications, and even alcohol and drug withdrawal. Epilepsy is the most common neurological disorder, affecting around 1 in 100 people worldwide. It is characterized by recurrent, unprovoked seizures that vary in severity from person to person. Epilepsy can be categorized into two major types: generalized and focal. In generalized epilepsy, seizures can involve multiple parts of the brain and can cause convulsions. Focal seizures, on the other hand, involve only one area of the brain. Treatment for epilepsy is based on the type and severity of the seizures and may include medication, surgery, lifestyle changes, and alternative therapies. Anti-epileptic drugs are the most commonly used treatment, and can help to reduce the frequency and severity of seizures. Surgery may be appropriate for specific types of epilepsy, such as temporal lobe epilepsy. Lifestyle changes, such as avoiding alcohol and reducing stress, can also have a beneficial effect. While there is currently no cure for epilepsy, managing seizures can greatly improve quality of life and reduce risk of injury. People with epilepsy can live full and active lives with the right treatment, support, and lifestyle modifications.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States